Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

ConferenceARIKAYCEBRINSUPRITPIPPositive

AI Analysis

Summary

Insmed will present Phase 3b ENCORE study data for ARIKAYCE and additional respiratory portfolio data at the European Respiratory Society Congress 2026, including efficacy and safety results for BRINSUPRI in non-cystic fibrosis bronchiectasis patients with NTM lung disease history.

Clinical Trial Data

Phase

Phase 3b

Outcome Details

Phase 3b ENCORE study data for ARIKAYCE to be presented

Importance:5/10

Sentiment:

0.30

respiratorybronchiectasisNTMlate-breaking dataconference presentation

Related Companies

$EMI

Read the original article

Published by PR Newswire Clinical Trials on September 3, 2026 11:00 AM

Read Original